• Antengene presented updated Phase II CLINCH data for ATG-022, a CLDN18.2 ADC, at the Evercore 2nd China Biotech Summit.
• In the 2.4 mg/kg cohort, ORR 42.4% (14/33), DCR 90.9% (30/33), median overall survival 12.85 months as of June 26, 2026.
• In the 1.8 mg/kg cohort, ORR 46.7% (14/30), DCR 86.7% (26/30), median overall survival not reached at 14.03 months follow-up.
• Grade ≥3 treatment-related adverse events in the 1.8 mg/kg cohort rose to 21% from 19.4%; dose reductions due to TRAEs were 9.7%.
• R&D platform update included TriGager tri-specific TCE logic-gates; ATG-207 αCD3–TGF-β fusion protein highlighted with preclinical data previously shown at EULAR 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608182100PR_NEWS_USPR_____CN28784) on August 19, 2026, and is solely responsible for the information contained therein.